We are live on ! Find out more
MC

Muhlenkamp & Co Portfolio holdings

AUM $345M
1-Year Est. Return 34.25%
This Fund
S&P 500
This Quarter Est. Return
+10.45%
1 Year Est. Return
+34.25%
3 Year Est. Return
+107.36%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$229M
AUM Growth
+$23.7M
Cap. Flow
+$6.7M
Cap. Flow %
2.93%
Top 10 Hldgs %
47.55%
Holding
39
New
5
Increased
18
Reduced
11
Closed
2

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$7.06M
2
DOW icon
Dow Inc
DOW
+$5.74M
3
LEN icon
Lennar Class A
LEN
+$5.42M
4
TEN
Tenneco Inc. Class A Voting Common Stock
TEN
+$4.9M
5
CVS icon
CVS Health
CVS
+$2.56M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$7.02M
2
GILD icon
Gilead Sciences
GILD
+$6.07M
3
CTSH icon
Cognizant
CTSH
+$5.3M
4
CCJ icon
Cameco
CCJ
+$4.3M
5
MSFT icon
Microsoft
MSFT
+$1.34M

Sector Composition

Rank Sector Weight
1 Technology 22.42%
2 Healthcare 22.38%
3 Consumer Discretionary 14.7%
4 Industrials 11.52%
5 Miscellaneous 10.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PKW icon
26
Invesco BuyBack Achievers ETF
PKW
$1.81B
$4.43M 1.94%
64,195
+32,795
+104% +$2.16M
WAB icon
27
Wabtec
WAB
$47.8B
$4.09M 1.79%
52,567
+20
+0% +$1.48K
CCJ icon
28
Cameco
CCJ
$43.9B
$3.38M 1.48%
380,132
-464,864
-55% -$4.3M
UNH icon
29
UnitedHealth
UNH
$356B
$3.05M 1.33%
10,369
+47
+0.5% +$12.3K
GILD icon
30
Gilead Sciences
GILD
$187B
$2.56M 1.12%
39,475
-93,134
-70% -$6.07M
GMLP
31
DELISTED
Golar LNG Partners LP
GMLP
$2.29M 1%
259,350
+21,730
+9% +$207K
PFE icon
32
Pfizer
PFE
$162B
$980K 0.43%
26,365
-711
-3% -$25.3K
EPD icon
33
Enterprise Products Partners
EPD
$84.1B
$700K 0.31%
24,855
– –
MS icon
34
Morgan Stanley
MS
$342B
$552K 0.24%
10,805
– –
CTSH icon
35
Cognizant
CTSH
$28.1B
$401K 0.18%
6,467
-85,758
-93% -$5.3M
BMY.RT
36
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$213K 0.09%
+70,665
New +$184K
RUSHB icon
37
Rush Enterprises Class B
RUSHB
$6.05B
$202K 0.09%
+14,951
New +$193K
CTVA icon
38
Corteva
CTVA
$58.6B
– –
-37,648
Closed -$1.05M
CELG
39
DELISTED
Celgene Corp
CELG
– –
-70,655
Closed -$7.02M
1
2

Similar funds

BMC
Bear Mountain Capital Seattle, Washington $345M AUM 13.71% 1-Year Est. Return
GSC
G&S Capital Denver, Colorado $345M AUM 32.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
LCM
Lonestar Capital Management San Francisco, California $345M AUM 80.24% 1-Year Est. Return
WFI
West Family Investments Carlsbad, California $345M AUM 46.29% 1-Year Est. Return
M2MC
Matthew 25 Management Corp Ambler, Pennsylvania $345M AUM 31.27% 1-Year Est. Return
FRA
Front Row Advisors Tiburon, California $345M AUM 39.04% 1-Year Est. Return
WWM
Westwood Wealth Management Los Angeles, California $345M AUM 113.04% 1-Year Est. Return

Muhlenkamp & Co's Q4 2019 Portfolio in Review

As of Q4 2019, Muhlenkamp & Co held 39 positions worth $229M, up 12% from $205M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Muhlenkamp & Co's Q4 2019 filing shows 5 new, 18 increased, 11 reduced and 2 closed positions. Its largest new stake was Bristol-Myers Squibb: 123,223 shares worth $7.91M. The largest sale was Celgene Corp, an estimated $7.02M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Muhlenkamp & Co's largest Q4 2019 buy was Bristol-Myers Squibb: 123,223 shares worth $7.91M.
  • Muhlenkamp & Co added most to Dow Inc in Q4 2019, an estimated $5.74M increase.
  • Muhlenkamp & Co's biggest Q4 2019 reduction was Gilead Sciences, cutting an estimated $6.07M.
  • Muhlenkamp & Co fully exited Celgene Corp in Q4 2019, selling an estimated $7.02M.
  • Muhlenkamp & Co's ten largest holdings make up 48% of its $229M portfolio in Q4 2019.
  • Muhlenkamp & Co opened 5 new positions and closed 2 in Q4 2019.
  • Muhlenkamp & Co's portfolio value rose 12% quarter-over-quarter to $229M.

Based on Muhlenkamp & Co's 13F filing for Q4 2019, filed 20 Feb 2020.